Recombinant Mouse CD32b/FCGR2B Protein (His Tag) | PKSM041016

Recombinant Mouse CD32b/FCGR2B Protein (His Tag) | PKSM041016 | Gentaur US, UK & Europe Disrtribition

Synonyms: Low affinity immunoglobulin gamma Fc region receptor II;Fc gamma receptor IIB;Fc-gamma RII;Fc-gamma-RIIB;FcRII;IgG Fc receptor II beta;Lymphocyte antigen 17; Ly-17; CD32; Fcgr2; Fcgr2b; Ly-17

Active Protein: N/A

Activity: Recombinant Mouse Low Affinity Immunoglobulin Gamma Fc Region Receptor II is produced by our Mammalian expression system and the target gene encoding Thr30-Pro210 is expressed with a 6His tag at the C-terminus.

Protein Construction: Recombinant Mouse Low Affinity Immunoglobulin Gamma Fc Region Receptor II is produced by our Mammalian expression system and the target gene encoding Thr30-Pro210 is expressed with a 6His tag at the C-terminus.

Fusion Tag: C-6His

Species: Mouse

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per μg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 21.6 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Background: Low affinity immunoglobulin gamma Fc region receptor II (CD32B) is a single-pass type I membrane protein and contains 2 Ig-like C2-type (immunoglobulin-like) domains. The inhibitory CD32B is expressed on B cells and myeloid dendritic cells. Ligation of CD32B on B cells downregulates antibody production and may, in some circumstances, promote apoptosis. Co-ligation of CD32B on dendritic cells inhibits maturation and blocks cell activation. CD32B may also be a target formonoclonal antibody therapy for malignancies.

Research Area: N/A